fulvestrant has been researched along with adenosine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feng, W; Kan, Y; Li, B; Yang, H; Zeng, M; Zhang, B; Zhang, L; Zheng, X | 1 |
1 review(s) available for fulvestrant and adenosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for fulvestrant and adenosine
| Article | Year |
|---|---|
Chinese yam extract and adenosine attenuated LPS-induced cardiac dysfunction by inhibiting RAS and apoptosis via the ER-mediated activation of SHC/Ras/Raf1 pathway.
Topics: Adenosine; Animals; Apoptosis; Cytokines; Dioscorea; Drugs, Chinese Herbal; Female; Fulvestrant; Heart; Heart Diseases; Lipopolysaccharides; Mitogen-Activated Protein Kinases; Myocardium; Myocytes, Cardiac; Proto-Oncogene Proteins c-raf; ras Proteins; Rats, Wistar; Receptors, Estrogen; Renin-Angiotensin System; Shc Signaling Adaptor Proteins | 2019 |